HR+ breast cancer

October 13, 2017

First Breast Cancer Patient in Japanese Trial Receives Entinostat

News

The first patient has been dosed in a pivotal Phase 2 clinical trial in Japan evaluating entinostat as a therapy for hard-to-treat breast cancers. Syndax Pharmaceuticals, which developed the therapy, said the trial (NCT03291886) ... Read more

March 9, 2016May 16, 2016

FDA Approves Combination Treatment of Faslodex/Ibrance for Certain Metastatic Breast Cancers

News

The U.S. Food and Drug Administration (FDA) has approved expanding the use of AstraZeneca’s breast cancer drug Faslodex (fulvestrant), in combination with Pfizer’s Ibrance (palbociclib), to treat advanced breast cancers (BC). The combination ... Read more

July 21, 2015July 22, 2015

New Treatment Option For Tough Breast Cancer Cases

News

Despite the advancment in techniques to address metastatic breast cancer, there are still very few effective treatment options. A recent phase 3 trial showed that palbociclib doubled the time to cancer recurrence in those suffering with hormone-receptor ... Read more

September 18, 2014September 18, 2014

Study Questions Benefit of Endocrine Therapy in Elderly Women with Low Risk Hormone Receptor Positive Breast Cancer

Breast Cancer News, News

Researchers at Fox Chase Cancer Center have showed that combining endocrine therapy and radiation therapy for breast conservation of women with hormone-receptor positive (HR+) invasive breast cancer may not be necessary ... Read more